Super Bowl 60: Food Brands Are in Denial as GLP-1s Come out Swinging

GLP‑1 drugs and related weight‑loss products are entering Super Bowl advertising (Novo Nordisk’s first Super Bowl buy; Ro and Hims & Hers also running spots) at the same time legacy consumption brands (beer, snacks, fast food) run traditional indulgence-driven creative. Empirical data cited include a 6% reduction in grocery spending within six months for GLP‑1 households (savory snacks down 10.1%), household penetration rising from 11% to over 16%, and a Morgan Stanley projection of a 75% reduction in alcohol consumption among GLP‑1 patients, implying meaningful secular demand risk for CPG/restaurant/alcohol companies that have yet to materially reframe brand positioning.

Analysis

Market structure: GLP-1 winners (Novo Nordisk/NVO and other pharma providers) gain durable demand and pricing power as household penetration climbed ~11%→16% in <12 months and could exceed 25% within 12–24 months; legacy consumption brands (snacks, beer, quick-serve restaurants) face 5–15% volume headwinds in high-frequency SKUs (savory snacks -10% observed) and will need to trade margin for reformulation/portioning. Competitive dynamics: incumbents with diversified portfolios (PEP) can partially offset US volume loss via international growth and beverages, but pure-play indulgence brands and low-margin CPGs have weakened pricing power and rising promotional risk. Supply/demand & cross-asset: GLP-1 supply tightening (short-term) supports biotech equities; longer term reduced commodity demand (corn, sugar, barley) could depress inputs and widen consumer staples credit spreads; watch beer/snack CDS and XLP vs. XLV correlations.

Risk assessment: Tail risks include regulatory price capping or Medicare negotiation of GLP-1s (materially compressing NVO’s margin within 12–24 months) and manufacturing/sterility recalls that temporarily choke supply and slow uptake. Timing: immediate (days) — marketing noise around Super Bowl; short-term (0–6 months) — measurable retail sell-through shifts and earnings-guide revisions; long-term (1–3 years) — secular consumption decline for targeted categories. Hidden dependencies: demand loss is income- and cohort-skewed (urban, higher-income early adopters), so premium brands and emerging markets may be insulated; catalysts: payer coverage decisions, new oral GLP-1 launches, and quarterly guides.

Trade implications: Tactical trades should overweight GLP-1 exposure and hedge US-centric CPG. Specific: accumulate 1–2% portfolio longs in NVO via 18–24 month LEAP calls (target +30–50% in 12–24 months) while hedging downside with a 15–20% stop. For PEP, reduce US-snack tilt and buy 3–6 month put spreads sized to cover 25–50% of current net exposure; consider long NVO / short PEP pair trade to isolate GLP-1 demand shock. Entry: act within 2–6 weeks to capture post-Super Bowl sentiment and ahead of Q1 guidance; exit or reweight if household penetration growth falls below +3ppt over a trailing 12 months.

Key Decisions for Investors

• Establish a 1–2% portfolio long in NVO via 18–24 month LEAP calls (e.g., Jan 2028 expiries) sized for a 30–50% upside target over 12–24 months; set a tactical stop-loss to trim if NVO equity falls 20% from entry or if household penetration growth slows to <+3ppt over a trailing 12 months.
• Reduce direct US-snacks/beverage exposure by 20–30% within 2 weeks—trim holdings in PEP (or XLP allocation) and purchase a 3–6 month PEP put spread sized to hedge 25–50% of remaining position (choose strikes ~5–8% OTM to limit premium).
• Implement a pair trade: long NVO (1.5% portfolio) / short PEP (1.0% portfolio) to isolate GLP-1 demand shock; rebalance after upcoming Q1 earnings or if Super Bowl-related sentiment shifts by >10% intraday.
• Buy 3–6 month volatility on CPG earnings risk: enter select long-put or strangle positions on high US-exposure names (PEP, BUD) ahead of Q1 guidance, allocating no more than 0.5–1% portfolio risk to options premium to capture potential re-rating.
• Within 30–90 days, monitor three catalysts as trade triggers: (1) FDA/Medicare pricing announcements, (2) quarterly guide revisions from PEP/BUD showing >3% downside to US consumption, and (3) new oral GLP-1 launches; if any occur, increase GLP-1 exposure and widen short CPG sizing by another 50%.